Раствор для ингаляций PUL-042
Международное непатентованное наименование
Раствор для ингаляций PUL-042
Торговое наименование
-
Производитель, страна
Pulmotect Inc., USA
Механизм действия
Prevent and treat respiratory complications in immunosuppressed cancer patients.
Опыт использования
PUL-042 is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection that lasts for days against all major classes of pathogens. Two previously completed phase I clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals. A Phase IIa viral challenge study is ongoing and Phase II studies are being planned to assess the effectiveness of PUL-042 in preventing respiratory tract complications in immunocompromised cancer patients.
Клинические исследования
1.
Название протокола
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Дата начала и окончания КИ
April 2020 - October 2020
Название организации, проводящей КИ
Pulmotect, Inc.
Страны
USA
Фаза
II
Кол-во пациентов
100
2.
Название протокола
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Дата начала и окончания КИ
April 2020 - October 2020
Название организации, проводящей КИ
Pulmotect, Inc.
Страны
USA
Фаза
II
Кол-во пациентов
200